Janus Henderson Group PLC Has $211.57 Million Stock Holdings in Sotera Health (NASDAQ:SHC)

Janus Henderson Group PLC decreased its stake in shares of Sotera Health (NASDAQ:SHC - Free Report) by 12.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,668,790 shares of the company's stock after selling 1,824,046 shares during the period. Janus Henderson Group PLC owned approximately 4.47% of Sotera Health worth $211,567,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SHC. Price T Rowe Associates Inc. MD increased its stake in Sotera Health by 25.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 59,480 shares of the company's stock valued at $715,000 after buying an additional 12,195 shares during the period. Public Employees Retirement System of Ohio increased its stake in Sotera Health by 14.6% during the 1st quarter. Public Employees Retirement System of Ohio now owns 47,377 shares of the company's stock valued at $569,000 after buying an additional 6,028 shares during the period. Comerica Bank boosted its position in shares of Sotera Health by 20.1% during the 1st quarter. Comerica Bank now owns 48,179 shares of the company's stock valued at $579,000 after purchasing an additional 8,074 shares in the last quarter. CWM LLC boosted its position in shares of Sotera Health by 86.1% during the 2nd quarter. CWM LLC now owns 2,146 shares of the company's stock valued at $25,000 after purchasing an additional 993 shares in the last quarter. Finally, Simplicity Wealth LLC bought a new position in shares of Sotera Health during the 2nd quarter valued at about $128,000. Institutional investors and hedge funds own 91.03% of the company's stock.

Wall Street Analysts Forecast Growth

SHC has been the subject of several research reports. Royal Bank of Canada restated an "outperform" rating and set a $17.00 price objective on shares of Sotera Health in a research report on Thursday, November 21st. Barclays raised their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, August 6th. Finally, Citigroup raised their price target on shares of Sotera Health from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.50.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares of the company's stock, valued at $739,705,974.03. The trade was a 16.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 55.12% of the company's stock.

Sotera Health Stock Performance

Shares of NASDAQ:SHC traded up $0.45 during trading on Wednesday, reaching $13.28. The stock had a trading volume of 2,508,816 shares, compared to its average volume of 1,347,193. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.44. The firm has a market capitalization of $3.76 billion, a price-to-earnings ratio of 53.12 and a beta of 1.96. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The stock has a fifty day simple moving average of $15.04 and a two-hundred day simple moving average of $14.06.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The company's revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.18 EPS. As a group, analysts anticipate that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.